We describe a rare case of a young patient with Crohn's disease, who accidentally was found to have developed renal cell carcinoma while on treatment with anti-TNF-α biologic agent. The patient was submitted to laparoscopic resection of the tumor. Up to December 2019 he is in perfect condition without receiving any kind of antineoplastic treatment. Clinicians should bear in mind this clinical combination in patients with Crohn's disease under treatment with biologic anti-TNF-α agents. Because the exact influence of anti-TNF-α biologic agents is largely unclear for now, the continuation of treatment might be a possible option.
Introduction
Although descriptions of the appearance of renal cell carcinoma (RCC) on the ground of ulcerative colitis have been previously described [1, 2, 3] , descriptions of RCC developed on the course of Crohn's disease (CD) are scarce [4] .
Patients with CD are at increased risk for both intestinal and extra-intestinal malignancies [5] and this risk is mainly Arch Clin Med Case Rep 2020; 4 (1): 153-157 DOI: 10.26502/acmcr.96550180
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attributed to chronic inflammation and immunosuppression [6, 7] . We describe here a young patient with CD who accidentally was found to have developed RCC during his treatment with anti-TNF-α biologic agent. The patient was submitted to laparoscopic resection of the RCC. Up to December 2019 he is in perfect condition without receiving any kind of antineoplastic treatment. 
Case Report

Discussion
Patients with CD seem to be at a relatively increased risk for development of RCC. In a population-based study in Chinese patients with IBD So et al, found that patients with CD had a higher risk of RCC (SIR 6.89; 95% CI, 2.22-21.37), compared with the general population [8] . Similarly, Wauters et al. [9] in a retrospective study including both, patients with IBD and RCC and patients with rheumatoid arthritis and RCC, found seven patients with renal cell carcinoma who were exposed to anti-TNF-a treatment. Compared to the group of patients with RCC without exposure to anti-TNF-a agent treatment, they were younger at age of diagnosis and they had received 
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immunosuppressives more frequently. However the standardized incidence ratios for IBD-RCC were not increased after anti-TNF exposure. Derikh et al found that pancolitis, penetrating CD, IBD related surgery, male gender, and older age at IBD onset were independent risk factors for RCC development. Also IBD patients had lower N-stage, lower M-stage, and underwent more frequently surgical treatment for RCC compared to the general population, thus having better survival rate [5] .
It is of interest that most of the relevant studies suggest that immunosuppressive and anti-TNFα therapy does not adversely affect disease free and overall survival in IBD patients following RCC diagnosis, meaning that treatment with biologic agents might be started or continued after RCC diagnosis in patients with low stage RCC [9] . The explanation could probably related to the fact that TNF-α can act as an autocrine tumor growth factor and that its presence is usually associated with poor prognosis. So despite concerns regarding a possible carcinogenic effect of treatment with anti-TNF-a factors, these agents have been previously considered as a therapeutic strategy for RCC, although other studies did not describe beneficial effect of anti-TNFα therapy in metastatic RCC [10] .
Concerning IBD patients with malignant disease in their past history we suggest that they should be managed jointly with the oncologist. Moreover, some factors including location, histology, and prognosis of the tumor, as well time from diagnosis and severity of the underlying inflammatory disorder, should be taken into account concerning the decision of restarting treatment with anti-TNF agent or not. However, mesalazine, corticosteroids, antibiotics, enteral and parenteral nutrition and surgery should freely continue [11] .
In conclusion, RCC may develop in patients with IBD treated with biologic anti-TNF-α agents. The diagnosis of RCC is usually incidental on routine abdominal imaging especially in young patients with IBD. Because the exact influence of anti-TNF-α biologic agents is largely unclear for now, the continuation of treatment might be a possible option.
